<table>
<thead>
<tr>
<th>Year</th>
<th>Topic</th>
<th>Authors/Producers</th>
</tr>
</thead>
<tbody>
<tr>
<td>1973</td>
<td>Highlights of This Issue 1973</td>
<td></td>
</tr>
<tr>
<td>1981</td>
<td>The Yin and Yang of Alloreactivity: Chronic Graft-versus-Host Disease and Leukemia Relapse</td>
<td>Saar Gill</td>
</tr>
<tr>
<td>1984</td>
<td>New Strategies in Glioblastoma: Exploiting the New Biology</td>
<td>Howard A. Fine</td>
</tr>
<tr>
<td>1995</td>
<td>Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy</td>
<td>Alexander Lin and Amit Maity</td>
</tr>
<tr>
<td>2001</td>
<td>Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?</td>
<td>Bruno Paiva, Noemí Puig, Ramón García-Sanz, and Jesús F. San Miguel on behalf of the Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study groups</td>
</tr>
<tr>
<td>2009</td>
<td>Genomic Landscape of Human Papillomavirus–Associated Cancers</td>
<td>Maria Rusan, Yvonne Y. Li, and Peter S. Hammerman</td>
</tr>
<tr>
<td>2029</td>
<td>Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial</td>
<td>Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns, Mona Martyn-Smith, Skye Simpson, Scott Mead, Marc D. Jones, Jasswinder S. Samra, Anthony J. Gill, Nicole Watson, Venessa T. Chiu, Jeremy L. Humphris, Angela Chou, Belinda Brown, Adrienne Money, Marina Pajic, Scan M. Grimmond, David K. Chang, David Thomas, Lucille Sebastian, Katrin Sjoquist, Sonya Yip, Nick Pavlakis, Ray Asghari, Sandra Harvey, Peter Grimison, John Simes, and Andrew V. Blankin, on behalf of the Australian Pancreatic Cancer Genome Initiative (APGI) and the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG)</td>
</tr>
<tr>
<td>2038</td>
<td>Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy</td>
<td>Ursula Amstutz, Steven M. Offer, Johanna Sistonen, Markus Joerger, Robert B. Diasio, and Carlo R. Largiadèr</td>
</tr>
<tr>
<td>2045</td>
<td>Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia</td>
<td>Brian Parkin, Peter Ouillette, Mehmet Yildiz, Kamlai Saiya-Cork, Kerby Shedden, and Sami N. Malek</td>
</tr>
</tbody>
</table>
# Table of Contents

## CANCER THERAPY: PRECLINICAL

### 2057 MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
Michael Weller, Ghazaleh Tabatabai, Barbel Kastner, Jörg Felsberg, Joachim P. Steinbach, Antje Wick, Oliver Schnell, Peter Hau, Ulrich Herrlinger, Michael C. Sabel, Hans-Georg Wirsching, Ralf Ketter, Oliver Bähr, Michael Platien, Jörg C. Tomn, Uwe Schlegel, Christine Marosi, Roland Goldbrunner, Roger Stupp, Krisztian Homicsko, Josef Pichler, Guido Nökhall, Jürgen Meixensberger, Peter Vajkoczy, Spyros Kollia, Johannes Hising, Guido Reifenberger, and Wolfgang Wick for the DIRECTOR Study Group

### 2065 PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

## BIOLOGY OF HUMAN TUMORS

### 2077 Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation—An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302
Jasdeep K. Saggar and Ian F. Tannock

### 2078 Rac1/Paki/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer
Vianey Gonzalez-Villasana, Enrique Fuentes-Mattei, Cristina Ivan, Heather J. Dalion, Cristian Rodriguez-Aguayo, Ricardo J. Fernandez-de Thomas, Burcu Aslan, Paloma del C. Monroig, Guermarie Velazquez-Torres, Rebecca A. Previs, Sunila Pradeep, Merin Kahraman, Huaiming Wang, Pinar Kanlikiliciler, Bulent Osoplat, George Calin, Anil K. Sood, and Gabriel Lopez-Berestein

### 2084 Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

### 2086 Preclinical Pharmacologic Evaluation of Prolactin Inhibiting Antagonist (Tarextumab) in Human Tumor Models

### 2096 Preclinical Pharmacologic Evaluation of Prolactin Inhibiting Antagonist (Tarextumab) in Human Tumor Models

### 2097 Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Sabrina Arena, Beatriz Bellusillo, Giulia Siravegna, Alejandro Martínez, Israel Cañadas, Luca Lazzari, Noelia Ferruz, Mariangela Russo, Sandra Misaie, Iria González, Mar Iglesias, Elena Gavilan, Giorgio Corti, Sebastijan Hobor, Giovanni Criciutfili, Marta Salido, Juan Sánchez, Alba Dalmases, Joaquim Bellmunt, Gianni De Fabritiis, Ana Rovira, Federica Di Nicolantonio, Joan Albanell, Alberto Bardelli, and Clara Montagut

Downloaded from clincancerres.aacrjournals.org on April 14, 2017. © 2015 American Association for Cancer Research.
# Table of Contents

## 2167  IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma

## 2177  Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach
Pleun Hombrink, Chopie Hassan, Michel G.D. Kester, Lorenz Jahn, Margot J. Pont, Arnoud H. de Ru, Cornelis A.M. van Bergen, Marieke Griffioen, J.H. Frederik Falkenburg, Peter A. van Veelen, and Mirjam H.M. Heemskerk

## Letters to the Editor

### 2187  RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Letter
Steven Sorscher

### 2188  RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response
Rona Yaeger and Leonard B. Saltz

## Retraction

### 2189  Retraction: Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

## Corrections

### 2190  Correction: Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer

### 2192  Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

## About the Cover

The cover shows establishment of blood brain barrier (BBB) tight junctions. Immunofluorescence staining demonstrates ZO-1 expression within the top endothelial layer of an in vitro BBB. For details, see the article by Jilaveanu and colleagues on page 2138 of this issue.